ライフサイエンスコーパス: partial remission

1 s had a complete response, and 1 patient had partial remission).

2 or at the start of cycle 25 (if at least in partial remission).

3 = .03), but not for remission (>/= very good partial remission).

4 d an objective response (13 complete and two partial remissions).

5 t recovery, and one (FLT3 wild-type AML) had partial remission.

6 te hematologic remission, and one achieved a partial remission.

7 One patient experienced an NCI WG partial remission.

8 rable disease, 10 (31%) achieved complete or partial remission.

9 uxetan given as consolidation of complete or partial remission.

10 Ten (50%) patients achieved complete or partial remission.

11 pe), four with incomplete CR, and three with partial remission.

12 , additional end points included complete or partial remission.

13 on [CR(u)] and 11 patients (27%) achieving a partial remission.

14 tients attained a complete remission and 1 a partial remission.

15 finition and follow-up of emerging mania and partial remission.

16 ignificantly poorer long-term prognosis than partial remission.

17 1 additional patient with HES has achieved a partial remission.

18 ents achieved and sustained CR, 3 nCR, and 4 partial remission.

19 d a complete remission, and 43 percent had a partial remission.

20 90% of this sample were either in full or in partial remission.

21 achieved complete remission and two achieved partial remission.

22 ansfer in two patients, one of whom showed a partial remission.

23 ss, 50% achieved complete while 21% achieved partial remission.

24 and 45% achieved complete while 15% achieved partial remission.

25 showed radiographic responses, four reached partial remission.

26 lete remission of DM, and 24 (10.6%) reached partial remission.

27 nd the first time for tumor recurrence after partial remission.

28 d dose level, 1 patient obtained a very good partial remission.

29 plete remission of diabetes and 5 (6.4%) had partial remission.

30 This patient is in an ongoing very good partial remission.

31 0.27 bleed per patient-week before achieving partial remission.

32 ith mantle cell lymphoma obtained an ongoing partial remission.

33 residual disease achieved either complete or partial remission.

34 ssion (CR), and 17 patients (29%) achieved a partial remission.

35 decreased among those achieving complete or partial remission.

36 nistration, 65 patients achieved complete or partial remission.

37 st 4 years of follow-up achieved complete or partial remission.

38 for more than 6 months, and three achieved a partial remission.

39 CRs without platelet recovery (CRp), and six partial remissions.

40 aneous complete remission and 2 patients had partial remissions.

41 26.1%), with four complete responses and six partial remissions.

42 40%; all responses in patients with CLL were partial remissions.

43 94% included 74% complete remissions and 20% partial remissions.

44 ee with non-small-cell lung cancer, achieved partial remissions.

45 rved 9 of 19 complete remissions and 3 of 19 partial remissions.

46 was 73% with 55% complete remissions and 18% partial remissions.

47 cluded six complete remissions (CRs) and two partial remissions.

48 (JAK) inhibitors, do not induce complete or partial remissions.

49 of 25 (71%) complete remissions and 10 (29%) partial remissions.

50 uding 12% complete responses and 12% nodular partial remissions.

51 uria value in complete remission (<0.3 g/g), partial remission (0.3-3.5 g/g), and no remission (>3.5

52 s excellent: 90.2% complete remission, 3.92% partial remission, 1.96% stable disease, 1.96% disease-r

53 a complete remission (2%), and five achieved partial remission (10%).

54 Three of 26 evaluable patients achieved partial remission (11.5%) and 13 patients achieved stabl

55 d one complete remission (21 months) and one partial remission (14 months) at the 480-mg/m(2)-dose le

56 lts: From the 100 evaluated patients, 35 had partial remission, 16 stable disease, 15 mixed response,

57 Two complete remissions and one partial remission (18%) were observed in 16 assessable p

58 s assessable for disease response, one had a partial remission (2 months), one has had stable disease

59 achieved objective response, including four partial remissions (2- to 6-month duration) and six comp

60 ctive responses (hematologic improvement, 3; partial remission, 2; or complete remission, 1) were see

61 P = .05), and remission rate (>/= very good partial remission; 23% v 47%, respectively; P = .02).

62 17 with complete remission (57%) and 10 with partial remission (33%).

63 were seen in 12 of 35 assessable patients (1 partial remission, 4 minor/mixed responses and 7 with st

64 ete remission (CR; 52%; 95% CI, 31 to 69) or partial remission (44%; 95% CI, 27 to 60) before immunot

65 SF in 77% of complete remission or very good partial remission, 45% of primary refractory, 25% of sec

66 assessable for response, 17 (71%) achieved a partial remission (46%) or complete remission (25%).

67 ed partial responses, with one in continuing partial remission 47 months after therapy.

68 chieved in 23 patients (18%), 36 (27%) had a partial remission, 55 (42%) had stable disease, and 8 pa

69 value was complete remission 89% (79 to 94), partial remission 75% (51 to 89), and no remission 64% (

70 , 6, 7.4, and 9.3 GBq, respectively, were in partial remission 8 wk after completing all 3 cycles.

71 after therapy (1/10 complete remission, 1/10 partial remission, 8/10 stable disease), and 9 of 13 pat

72 reater than 40% of patients with complete or partial remission, a significant 5-year survival benefit

73 tiation of corticosteroids, with complete or partial remission achieved in most patients.

74 ved remission, and 21 patients (47%) reached partial remission after 1 cycle of BCDT (mean followup 3

75 Rates of partial remission after 2 weeks of treatment with fluoxe

76 in first complete remission and 13 in first partial remission after conventional therapy.

77 experienced relapse, two of whom re-entered partial remission after resuming daratumumab therapy.

78 chronic lymphocytic leukaemia in complete or partial remission after second-line or third-line treatm

79 progressed during paclitaxel treatment had a partial remission after the addition of cyclosporin A (r

80 Thirty-four (19%) of 184 had a partial remission and 55 (31%) of 184 had no response or

81 achieved in 25% of 177 patients, and nodular partial remission and partial remission were achieved in

82 The third patient had an objective partial remission and relapsed at 12 months after infusi

83 of recurrence-free survival after achieving partial remission and remained significant after adjustm

84 ibrutinib for 6 additional months; those in partial remission and/or with BM MRD 0.01%, the majority

85 % confidence interval [CI], 33-62), with 22% partial remissions and 25% MR.

86 When partial remissions and anxiety disorder diagnoses classi

87 treatment led to a 67% response rate (three partial remissions and one complete remission).

88 hieved complete remission, 14 of 51 achieved partial remission, and 1 of 51 had progressive disease.

89 eved a complete response (CR), one a nodular partial remission, and 10 patients a partial remission (

90 ) achieved complete remission, four achieved partial remission, and 21 failed therapy.

91 ssion (CR), 12% of patients (n = 8) achieved partial remission, and 9% of patients (n = 6) died of in

92 Partial response, very good partial remission, and complete response were documented

93 but best monotherapy responses are typically partial remission, and patients must remain on treatment

94 Patients with recurrent disease, partial remission, and progressive disease were retreate

95 Probabilities of full remission, partial remission, and relapse during this year were exa

96 he patients (N = 28) demonstrated at least a partial remission, and there was no difference between t

97 on as persistent proteinuria <0.3 g/24 h and partial remission as persistent proteinuria <3 g/24 h, e

98 as defined as minimal or no BDD symptoms and partial remission, as meeting less than full DSM-IV crit

99 h FC offers patients who achieve complete or partial remission, as well as those who have fludarabine

100 tcomes included determination of complete or partial remission at 24 months and occurrence of adverse

101 A secondary end point was partial remission at 24 weeks.

102 and 28 LAGB participants (28.6%) experienced partial remission at 3 years.

103 n patients transplanted in first complete or partial remission at 4 years (66% vs 36%; P = .062).

104 Complete or partial remission at 6 months after rituximab treatment

105 sed treatment was significantly superior for partial remission at EOT but not at follow-up.

106 ailure-free survival (defined as less than a partial remission at the end of induction, relapse, prog

107 one patients (70%) were in first complete or partial remission at the time of the ASCT.

108 6 were in complete remission, and 8 were in partial remission before allo-HCT with 12 grafts from un

109 clinically: 59% and 88% attained complete or partial remission by 12 and 24 months, respectively, com

110 not allow further separation of patients in partial remission by risk of recurrence (P=.9).

111 sion for 3 to 21 months, and two patients in partial remission continue to improve after 14 and 19 mo

112 Primary outcome was complete/partial remission (CR/PR) as defined by IPNA/KDIGO guide

113 Patients in complete/very good partial remission (CR/VGPR) after P6 received myeloablat

114 (22%), giving a complete remission/very good partial remission (CR/VGPR) rate of 78%.

115 th 2 patients achieving partial response and partial remission cytolytic response, respectively.

116 However, total remission rates (complete and partial remission) did reach significance in post hoc an

117 on in 72%, nodular partial remission in 10%, partial remission due to cytopenia in 7%, and partial re

118 artial remission due to cytopenia in 7%, and partial remission due to residual disease in 6%.

119 over 30% of children underwent a complete or partial remission during the 2.5 years of therapy, but t

120 s in C1q negative group achieved complete or partial remission during the follow up period (P = 0.003

121 h a homozygous ADCK4 frameshift mutation had partial remission following CoQ10 treatment.

122 Of the 12 patients, 1 had partial remission for 1 y, another had a minor response

123 ission, surgical free of disease, continuous partial remission for 2+ years), time to treatment failu

124 ents with ovarian/fallopian tube cancers had partial remissions for 5.2 and 9.2 months.

125 ed complete remissions and 26% have achieved partial remissions for an overall response of 83%.

126 Partial remission (for comparison purposes) was defined

127 The overall response rate (complete or partial remissions) for all 26 dogs was 46% (12 of 26),

128 In addition, 48% of patients achieved a partial remission, for an overall response rate of 65% (

129 Patients had to be in full or partial remission from depression.

130 was most evident for patients in complete or partial remission (good risk; GR) at ASCT.

131 Tumor responses included partial remission (>/= 50% reduction in tumor volume) in

132 mg/d with <15% decline in baseline eGFR) or partial remission (>50% reduction in 24-hour proteinuria

133 All patients who achieved partial remission had a normal baseline LDH.

134 modulatory drugs-patients who do not achieve partial remission have a significantly shorter overall s

135 Three patients achieved and continue in partial remission (hemoglobin at least 10 g/dL without t

136 One patient with partial remission in 1 of 2 treated skin areas experienc

137 95%, with complete remission in 72%, nodular partial remission in 10%, partial remission due to cytop

138 disclosed a complete tumor remission in 3, a partial remission in 12 and a stable disease in 6 patien

139 nse evaluation ((68)Ga-PSMA PET/CT) revealed partial remission in 14, stable disease in 2, and progre

140 ion occurred in 49 of the 65 patients (75%), partial remission in 15 (23%), and no response in 1 (2%)

141 disease were complete remission in 43 (58%), partial remission in 19 (26%), and no response in 12 (16

142 colitis were complete remission in 34 (54%), partial remission in 19 (30%), and no response in 10 (16

143 Follow-up revealed partial remission in 2 patients, a mixed response in one

144 treated with (177)Lu-DOTA-JR11, resulting in partial remission in 2 patients, stable disease in 1 pat

145 was complete remission in 2 patients (4.3%), partial remission in 21 (44.7%), stable disease in 18 (3

146 as achieved in 72 of 99 patients (72.7%) and partial remission in 24 of 99 patients (24.2%).

147 n leading to a complete remission in 72% and partial remission in 26% after 3 ([Formula: see text]0.0

148 Contrast-enhanced CT revealed partial remission in 5, stable disease in 13, and progre

149 nsplantation (ASCT) during first complete or partial remission in 52 patients with poor-risk aggressi

150 tion in lupus in the last year, complete and partial remission in lupus nephritis has been achieved i

151 mens, with occasional complete remission and partial remission in some patients.

152 nd EBV-CTLs each induced durable complete or partial remissions in 73% and 68% of treated patients in

153 uced complete remissions in 4 of 19 mice and partial remissions in the remainder.

154 New definitions of complete and partial remission incorporate clinical, hematological, a

155 mplete haematological recovery, and 25 (10%) partial remission INTERPRETATION: Gilteritinib had a fav

156 a first diagnosis of AHA remains high until partial remission is achieved, and weekly measured FVIII

157 Complete remission, partial remission, marrow complete remission, or haemato

158 eveloped an acute phase of EAE followed by a partial remission, middle-age males suffered severe chro

159 ponse to CLL therapy was complete (n = 4) or partial remission (n = 1) and stable disease (n = 1).

160 in complete remission (n = 24) and those in partial remission (n = 11).

161 tocol entry: complete remission or very good partial remission (n = 33), primary refractory (n = 33),

162 Complete (n=5) or partial remission (n=5) was achieved in T-cell acute lym

163 tients responded (complete remission, n = 2; partial remission, n = 1).

164 Partial remission occurred in 21 of the 71 patients (29.

165 A complete or partial remission occurred in 7 patients (21%), with a m

166 Response (complete/partial remission) occurred in 26 of the 28 patients (93

167 documented in 36%, with five complete and 11 partial remissions, occurring after a median of 6 weeks

168 se mice with CG or in the Tg26 mice promoted partial remission of proteinuria and ameliorated kidney

169 rior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was su

170 imary outcome was a composite of complete or partial remission of proteinuria at 24 months.

171 come was a combined end point of complete or partial remission of proteinuria at 6 months.

172 e for inducing and maintaining a complete or partial remission of proteinuria in patients with this c

173 Complete and partial remission of proteinuria within 12 months of dis

174 Overall, 36% achieved partial remission of proteinuria, 32% had no remission,

175 epletion, many patients with MN achieve only partial remission of proteinuria, which may be explained

176 or 40% decline in eGFR, and complete and/or partial remission of proteinuria.

177 was associated with a greater likelihood of partial remission of type 2 diabetes compared with diabe

178 ved complete remissions (CRs), four achieved partial remissions, one had stable lymphoma, and two wer

179 sion (CR) was achieved in 22 patients (14%); partial remission or hematologic improvement occurred in

180 rch evaluated factors linked to complete and partial remission or improvement of T2DM after laparosco

181 ent responses, with many experiencing either partial remission or no remission of proteinuria.

182 redict patients who would attain complete or partial remission or no-response to first-line chemother

183 Disease control rates (complete or partial remission or stable disease in patients with for

184 receiving the cyclic regimen had complete or partial remission (OR, 0.61; 95% CI, 0.23 to 1.63).

185 f these, 66% maintained a complete and 34% a partial remission over the study period.

186 and included one complete remission and four partial remissions (overall response rate, 11.6%; 95% co

187 were highly expressed in non-responders and partial remission patients than in complete remission pa

188 If in complete or partial remission, patients proceeded to consolidation w

189 Three patients (11%) achieved a partial remission (PR) (durations, 7, 8, and 19 weeks) a

190 Six patients (15%) achieved a partial remission (PR) (durations: 8, 14, 18, 28, 56, an

191 2) relapse after first transplant in 20, (3) partial remission (PR) after first transplant in eight,

192 large B-cell lymphoma (DLBCL) who achieve a partial remission (PR) after salvage chemotherapy is not

193 atients with aGHVD were nonresponsive and in partial remission (PR) after steroids, respectively, and

194 All responders had at least a partial remission (PR) after the first therapy dose of (

195 Patients who did not achieve at least a partial remission (PR) after two courses or whose diseas

196 erwent ABMT in first complete remission (CR)/partial remission (PR) following CHOP induction.

197 Complete remission (CR) was achieved in 70%, partial remission (PR) in 18%, nodular PR in 3%, for an

198 f complete remission (CR) in 51% (24 of 47), partial remission (PR) in 38% (1 8 of 47), and stable di

199 (CR) in 2 patients with Hodgkin disease and partial remission (PR) in a patient with refractory mant

200 ete remission in three patients (11.5%), and partial remission (PR) in three patients (11.5%).

201 ission (CR) of pancreatic cancer (10 mg/m2), partial remission (PR) of malignant melanoma in two pati

202 script evaluates complete remission (CR) and partial remission (PR) of proteinuria as surrogate end p

203 Being in partial remission (PR) or complete remission (CR) at HCT

204 herapy, many patients experience a transient partial remission (PR) phase, also known as the honeymoo

205 complete remission (CR) rate was 50% and the partial remission (PR) rate was 37%.

206 The complete remission (CR) plus partial remission (PR) rate was 47% (95% confidence inte

207 All 5 patients achieving a clinical partial remission (PR) studied by cPCR were positive.

208 Complete remission (CR) or sustained partial remission (PR) was achieved in 68% of HCT recipi

209 at is traditionally deemed irreversible, but partial remission (PR) with temporary reversal of hyperg

210 d partial remission (VGPR), and nine were in partial remission (PR), according to criteria from Inter

211 ; 5 are in complete remission (CR), 2 are in partial remission (PR), and 10 have stable or progressiv

212 esponse categories: complete remission (CR), partial remission (PR), and clinical improvement (CI).

213 in complete remission (CR), five achieved a partial remission (PR), and four had stable disease (SD)

214 We defined complete remission (CR), partial remission (PR), and relapse as proteinuria </=0.

215 n very good partial remission (VGPR), one in partial remission (PR), and two had microscopic foci in

216 nodular partial remission, and 10 patients a partial remission (PR), for an overall response (OR) rat

217 eved complete remission (CR), and 3 achieved partial remission (PR), for an overall response rate of

218 Of four patients who achieved a partial remission (PR), one remains progression-free at

219 Secondary end points were partial remission (PR), symptoms, compliance, esophageal

220 Six of 18 assessable patients had a partial remission (PR), with a median time to disease pr

221 ll response rate was 76% with 60% CR and 16% partial remission (PR).

222 , 40 (80%) achieved CR, and 9 (18%) achieved partial remission (PR).

223 remission (CR); 18 patients (21%) achieved a partial remission (PR); and 1 patient's response was una

224 Partial remission (PR; defined as no active bleeding, FV

225 ion (CR), one unconfirmed CR (CRu), and four partial remissions (PR) among patients with follicular n

226 three complete remissions (CRs; 8%) and five partial remissions (PR; 14%); response to melphalan (n =

227 verall response rate (complete response plus partial remission [PR] plus minimal response [MR]) was 7

228 n first response (complete remission [CR] or partial remission [PR]) with poor prognostic features, w

229 mantle cell non-Hodgkin lymphoma (NHL) (CR + partial remission [PR]), and high-grade NHL-CR had the l

230 teratoma-positive primary tumor, resectable partial remission [PR]), n = 90; group D [serologic CR,

231 d complete remission [CR] and 3 patients had partial remission [PR]).

232 rovement rate (OIR: complete remission [CR], partial remission [PR], marrow CR [mCR], or hematologic

233 m remission status (complete remission [CR], partial remission [PR], no remission [NR]).

234 n = 17; 75% complete remissions [CR] and 10% partial remissions [PR]), whereas 3 patients had progres

235 n (complete remission) or relatively benign (partial remission) prognosis.

236 responses were 1 complete remission (CR), 6 partial remissions (PRs), and 5 patients with stable dis

237 6%) complete remissions (CRs) and 12 (26.6%) partial remissions (PRs), for a CR plus PR rate of 33.3%

238 s (CRs plus unconfirmed CRs [CRu's]) and 23% partial remissions (PRs).

239 ematologic recovery [CRi]) and 13 (17%) with partial remissions (PRs).

240 ORR was 41% (8 complete remissions [CRs], 6 partial remissions [PRs]), and ORR was 54% in AITL (5 CR

241 The partial remission rate (PR) after two cycles of DTPACE w

242 te was 70% (95% CI, 63% to 76%), the nodular partial remission rate was 10%, and the partial remissio

243 ular partial remission rate was 10%, and the partial remission rate was 15%, for an overall response

244 Secondary outcome measures included partial remission rates (>85% of expected weight for hei

245 Long-term complete and partial remission rates were 24% and 26%, respectively,

246 Partial remission rates were 39%, 70%, and 83% after 1,

247 Patients in complete remission or partial remission received six reinduction courses, alte

248 with IIS resistance, complete remission, and partial remission, respectively; 27% in children with a

249 A partial-remission response (defined as an insulin dose-a

250 in the cyclosporine group had a complete or partial remission (risk difference, 40 percentage points

251 in the cyclosporine group had a complete or partial remission (risk difference, 8 percentage points;

252 ries are listed: complete remission (CR) and partial remission signify treatment effects that are con

253 Anti-FVIII IgA-positive patients achieved partial remission similar to anti-FVIII IgA-negative pat

254 ategorized the lesions into three subgroups (partial remission, stable disease, progression) based on

255 objective response, defined as complete and partial remission, tested at a one-sided significance le

256 ver 11 to 23 months after treatment; 1 had a partial remission that persisted for 12 months; 1 has ha

257 year complete clinical remission, and 3% had partial remission; the other 3% developed chronic migrai

258 ints included overall response (complete and partial remission), time to overall response, and advers

259 Of the patients with partial remission to protocol treatment, 8 achieved remi

260 percent of patients had achieved less than a partial remission to their most recent therapy and would

261 chieved complete remission, 8 (29%) achieved partial remission (treatment eventually failed in 4 of t

262 ogic normalization (HN; complete remission + partial remission + trilineage hematological improvement

263 ated with 2-CdA, and all achieved at least a partial remission; two of these have already relapsed wi

264 One patient had a partial remission; two others had a reduction in blasts

265 omplete remission (CR), 12 were in very good partial remission (VGPR), and nine were in partial remis

266 in complete remission CR, eight in very good partial remission (VGPR), one in partial remission (PR),

267 om BDD was only 0.09, and the probability of partial remission was 0.21.

268 Partial remission was a change from a BILAG A or B score

269 Complete remission or partial remission was achieved in 247 patients (76%).

270 Partial remission was defined as a reduction in endoscop

271 Partial remission was defined as independence from trans

272 on was demonstrated in 34 patients (44%) and partial remission was demonstrated in 39 patients (50%).

273 Although the cumulative incidence of partial remission was lower in the Rtx group, rates of c

274 The percentage in remission versus partial remission was not statistically significant betw

275 A partial remission was seen by CT 1 mo after the first ra

276 20% improvement in 5 of 6 domains, and ASAS partial remission were achieved by 61%, 44%, and 56% of

277 patients, and nodular partial remission and partial remission were achieved in 16% and 32% of patien

278 Complete remission (CR) and partial remission were achieved in 55% and 15% of patien

279 ansplantation in first or second complete or partial remission were eligible.

280 Three complete remissions and one partial remission were observed in 30 assessable AML pat

281 ymphoma, and four of the six patients with a partial remission were positron emission tomography nega

282 h TRD who were moderately depressed or BD in partial remission were randomized to 8 weekly EPO (40,00

283 10% to 17% of azacitidine-treated patients; partial remissions were rare; 23% to 36% of patients had

284 ifth Edition (DSM-5) criteria for AN or pAN (partial remission) were recruited to a study conducted a

285 initially responded with either complete or partial remission, whereas nonresponders experienced a r

286 a significantly higher rate of complete and partial remissions, while in first-line therapy a signif

287 ine, 11 had a complete remission and 2 had a partial remission with BL22.

288 on soon after the induction of a complete or partial remission with conventional-dose chemotherapy do

289 probabilities of complete and of complete or partial remission with rituximab were 0.42 (95% CI, 0.26

290 FL who achieved either complete or very good partial remission with salvage chemotherapy were randoml

291 atients (33%) achieved a major response (all partial remissions), with a median time to response of 3

292 Four patients achieved partial remission, with a >50% reduction in the glucocor

293 above salivary gland uptake translated into partial remission, with an odds ratio (OR) of 60.265 (95

294 Elevated LDH implied a reduced chance for partial remission, with an OR of 0.094 (95% CI, 0.017-0.

295 are in complete remission and 5 are in good partial remission without treatment (together, 12 of 17

296 in 17 patients (3 complete remissions and 14 partial remissions), yielding an intent to treat respons